Want to see MESO full AI Analyst Report?
MESO Stock Chart & Stats
$17.19
-$0.67(-4.38%)
At close: 4:00 PM EDT
$17.19
-$0.67(-4.38%)
Day’s Range― - ―
52-Week Range$11.89 - $21.50
Previous CloseN/A
Volume88.14K
Average Volume (3M)264.72K
Market Cap
$1.61B
Enterprise Value$1.78B
Total Cash (Recent Filing)$102.91M
Total Debt (Recent Filing)$127.33M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 04, 2027EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding130,129,800
10 Day Avg. Volume336,027
30 Day Avg. Volume264,723
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.08
Price to Sales (P/S)14.50
P/FCF Ratio-39.17
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue14.73
Enterprise Value/Gross Profit18.49
Enterprise Value/Ebitda-40.69
Forecast
1Y Price Target
$37.00Price Target Upside115.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$209.64M
Bulls Say, Bears Say
Bulls Say
RYONCIL Commercial TractionRYONCIL has moved Mesoblast into commercial operations with meaningful first-year revenue, broad treatment-center adoption, and extensive reimbursement coverage. This infrastructure can support continued penetration and provides a durable base for future label expansion beyond the current pediatric indication.
Late-stage Pipeline ProgressMultiple programs have advanced into registrational or pivotal stages, creating potential pathways to broaden the company beyond RYONCIL. Completed treatment and active enrollment reduce development uncertainty compared with earlier research programs, although future value remains dependent on clinical and regulatory outcomes.
Improving Financial TrajectoryThe sharp reduction in losses and cash consumption indicates improving operating leverage as commercialization scales. Although Mesoblast remains unprofitable, better economics from RYONCIL can preserve resources for late-stage programs and extend financial flexibility over the next several quarters.
Bears Say
Persistent Losses And Cash BurnMesoblast has not yet demonstrated self-funding operations, with recurring negative operating and free cash flow alongside substantial net losses. Continued investment in trials, commercialization, and development may require external financing, limiting financial flexibility until revenue growth reaches operating breakeven.
RYONCIL Revenue ConcentrationDependence on a single marketed therapy leaves near-term results sensitive to adoption, reimbursement, and execution for RYONCIL. Pipeline candidates are not yet commercial contributors, so setbacks in the lead product or slower uptake could materially affect revenue growth and funding capacity.
Long And Uncertain Development TimelinesImportant label expansions and new-product revenue remain several years away and depend on enrollment, trial results, and regulatory review. These timelines delay diversification beyond RYONCIL and increase the period in which Mesoblast must fund development while still carrying execution uncertainty.
Mesoblast News
MESO FAQ
What was Mesoblast Ltd’s price range in the past 12 months?
Mesoblast Ltd lowest stock price was $11.89 and its highest was $21.50 in the past 12 months.
What is Mesoblast Ltd’s market cap?
Mesoblast Ltd’s market cap is $1.61B.
When is Mesoblast Ltd’s upcoming earnings report date?
Mesoblast Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 130 days.
How were Mesoblast Ltd’s earnings last quarter?
Mesoblast Ltd released its earnings results on Aug 26, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.06.
Is Mesoblast Ltd overvalued?
According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued.
Does Mesoblast Ltd pay dividends?
Mesoblast Ltd does not currently pay dividends.
What is Mesoblast Ltd’s EPS estimate?
Mesoblast Ltd’s EPS estimate is -0.14.
How many shares outstanding does Mesoblast Ltd have?
Mesoblast Ltd has 130,129,800 shares outstanding.
What happened to Mesoblast Ltd’s price movement after its last earnings report?
Mesoblast Ltd reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went up 7.957%.
Which hedge fund is a major shareholder of Mesoblast Ltd?
Currently, no hedge funds are holding shares in MESO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.00 (115.24% Upside)
$37.00 (115.24% Upside)
Blogger Sentiment
Bullish
MESO Sentiment 75%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.18%
12-Months-Change
Fundamentals
Return on Equity
-10.06%
Trailing 12-Months
Asset Growth
-1.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mesoblast Ltd
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
MESO Company Deck
MESO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive: Mesoblast reported a successful first full commercial year for RYONCIL with $115M revenue, very high reported gross profit, strong real‑world efficacy signals, important pipeline milestones (IND cleared for Duchenne, completion of 350‑patient low back pain pivotal treatment, ongoing adult GvHD randomized trial), and materially reduced cash burn and net loss (44% reduction). Offsetting items include continued net losses ($57.5M), ongoing cash usage ($43.8M), dependence on a single commercial product today, financing costs (125M credit line at 8%), and multi‑year timelines and enrollment/regulatory risks for several label expansions. Overall, the positive commercial launch, improved financial trajectory, and advanced pipeline milestones outweigh the remaining financial and execution risks.View all MESO earnings summariesMESO Stock 12 Month Forecast
Average Price Target
$37.00
▲(115.24% Upside)
Technical Analysis
Ownership Overview
26.06% Insiders
<0.01% Mutual Funds
0.10% Other Institutional Investors
73.32% Public Companies and
Individual Investors